Under a non-exclusive agreement, Germantown, Maryland-based Senseonics Holdings Inc. will use its Eversense sensor, the first and only fluorescence-based implantable continuous glucose monitoring (CGM) sensor system, to integrate glucose readings into TypeZero Technologies Inc.'s inControl software platform. The software includes a series of algorithms for artificial pancreas solutions. Financial details of the agreement were not revealed.
Senseonics' Eversense sensor is unique in that it continuously measures glucose levels for up to 90 days, which eliminates the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?